

**REMARKS/ARGUMENTS**

With entry of this amendment, claims 98-147 are pending. Claims 1-97 have been cancelled, and claims 123-147 newly added. No claim amendment or claim cancellation should be construed as an acquiescence in any ground of rejection.

***Sequence Listing***

Applicants request entry of this amendment in adherence with 37 C.F.R. §§ 1.821-1.825. This amendment is accompanied by a computer disk containing the Sequence Listing in computer readable form, and a paper copy of the Sequence Listing that has been prepared from the computer disk. The information contained in the computer disk was prepared using the software program "PatentIn" and is identical to the paper copy. This amendment adds no new matter.

The instant amendment also adds a sequence identifier (SEQ ID NO:1) to the specification in accordance with 37 C.F.R. 1.821-1.825. This amendment adds no new matter as well.

***Claim Rejections***

**35 U.S.C. § 112, first paragraph**

Claims 98-122 are rejected under 35 U.S.C. § 112, first paragraph, for allegedly lacking enablement for a method for prophylactically or therapeutically treating Alzheimer's disease in a mammal by administration of A $\beta$  peptide. As the outstanding Office Action states that these methods are enabled for treating Alzheimer's disease in humans, Applicants have amended claim 98 and drafted new claim 123 accordingly. All amendments are for purposes of expediting prosecution and should not be construed as an acquiescence in any ground of rejection.

**35 U.S.C. § 112, second paragraph**

Claims 98-122 also stand rejected as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter the applicant regards as the invention.

Claim 98 has been amended to overcome the outstanding Office Action's objections under 35 U.S.C. 112. The claim has been revised to: recite a method for treating Alzheimer's disease in a human, clearly identify the nature of the sufficient amount of aqueous composition comprising A $\beta$ , specifically define the response effected by use of the claimed method, identify the material filtered in the claim consistently as a "suspension", and to delete the phrase identified as redundant in the outstanding Office Action. Support for the amendments to the claim are found, e.g., on page 2, lines 4-13, page 6, lines 12-16, and page 32, lines 5-9.

Claim 99 has been amended to delete the term "an effective amount", which was termed "vague and ambiguous" in the outstanding Office Action. Support for the amendments to the claim is found, e.g., on page 17, lines 2-11 of the instant application.

Claims 108 and 117 have been amended to recite a pharmaceutically acceptable buffer. Support for these amendments is found, e.g., on page 12, lines 18-22 of the instant application.

Claim 110 has been amended for clarification, i.e., to identify the sucrose concentration of the sterile suspension. Support for this amendment is found, e.g., on page 29, lines 25-26 of the instant application.

Claim 116 has been amended to provide an A $\beta$  concentration and to identify the result of the "effective amount of QS21", i.e., to form a visually clear suspension. Support for the amendments to the claim is found, e.g., on on page 18, lines 17-18, and page 15, lines 4-13.

Claim 118 has been amended to identify the result of the "effective amount of DPPC", i.e., to form a visually clear suspension. Support for the amendments to the claim is found, e.g., on page 15, lines 4-13.

Claims 121 and 122 have been amended to recite parenteral administration. Support for these amendments is found, e.g., on page 10, lines 13-14, and p.19, line 33 of the instant application.

Claims 99 and 120 have been amended to correct the antecedent basis.

Appl. No. 09/980,586  
Amdt. dated August 23, 2004  
Reply to Office Action of February 23, 2004

PATENT


If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Anina D. Murphy  
Reg. No. 51,049

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC:adm  
60247902 v1



## SEQUENCE LISTING

<110> Hirtzer, Pamela  
Patel, Naina

<120> Compositions Of A-Beta Peptide And Processes For Producing Same

<130> 15270J-006113US

<140> US 09/980,586  
<141> 2000-06-01

<150> PC WO 00/72870  
<151> 2000-06-01

<150> US 60/137,047  
<151> 1999-06-01

<160> 1

<170> PatentIn version 3.2

<210> 1  
<211> 42  
<212> PRT  
<213> Homo sapiens

<400> 1

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala  
35 40